Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

With his research group "Chromatin and SUMO Physiology," the molecular biologist has shown that the chemotherapeutic agent sorafenib actively remodels skeletal muscle cells and thus triggers cachexia.

Sorafenib demonstrated a high-level of efficacy in patients with advanced HCC in these two clinical trials and was rapidly approved for use in clinical practice. Physicians should adequately ...

Current status of physicians’ perception of HCC conversion/downstaging therapy: A nationwide survey in China. A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination ...

Dana Walker, vice president, Opdivo global programme lead, BMS, said: “HCC is the predominant type of liver cancer globally, including in the EU, and when diagnosed at the advanced or unresectable ...